MedWatch

Onxeo loses half its market cap after failed cancer study

The Danish-French biotech company Onxeo did not succeed with a phase III trial with drug candidate Livataq in patients with hepatocellular carcinoma (HCC). Now, the share price has dropped by nearly 50 percent and several banks have downgraded the price target of the Onxeo share.

Photo: Onxeo, PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

FDA vil lette vejen til markedet for medicin mod Alzheimers

De amerikanske lægemiddelmyndigheder vil lempe kravene til godkendelse af lægemidler mod Alzheimers, fordi forskning viser, at sygdommen indtræder tidligere end hidtil antaget. Lægemiddeludviklingen og godkendelse heraf derfor skal tilpasses derefter, mener FDA-boss Scott Gottlieb.

Related articles